Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Theratechnologies (THTX) announced that the FDA has approved the Company’s supplemental Biologics License Application, or sBLA, for the F8 ...

NPPA notifies revised prices of certain products based on WPI increase: Gireesh Babu, New Delhi Saturday, March 29, 2025, 08:00 Hrs [IST] The National Pharmaceutical Pricing Autho ...

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

Joshua Kaufman, MD, of CDPHP, discusses the significance of long-acting injectables (LAIs) in improving adherence, reducing the risk of relapse, and preventing hospitalizations.

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Theratechnologies (Nasdaq: THTX) has received approval from the US Food and Drug Administration for Egrifta WR (tesamorelin), ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.

NPPA asks Bayer Zydus Pharma to continue selling Urografin for one more year: Gireesh Babu, New Delhi Saturday, March 29, 2025, 08:00 Hrs [IST] The National Pharmaceutical Pricing ...